Archive


Category: $650M

  • Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M

    Shots: PTC Therapeutics to receive $650M as upfront in cash in exchange for ~43% of the risdiplam royalties, up to a specified amount while PTC maintains the majority of the risdiplam royalty stream and retains all economics associated with up to ~$400M in remaining regulatory and commercial milestones The collaboration enables PTC to further develop […]